RDIF and Landsteiner Scientific agree to supply 32 million doses of Sputnik V vaccine to Mexico
Moscow, September 9, 2020 – The Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, and Landsteiner Scientific pharmaceutical company have announced an agreement for the supply of 32 million doses of the Russian Sputnik V vaccine to Mexico (25% of population). Deliveries are expected to start in November 2020 subject to approval by Mexico’s regulators.
As part of the agreement with RDIF, Landsteiner Scientific as a partner of RDIF would distribute the vaccine in Mexico.
On August 11, the Sputnik V vaccine developed by the Gamaleya National Research Institute of Epidemiology and Microbiology was registered by the Ministry of Health of Russia and became the world’s first registered vaccine against COVID-19 based on human adenoviral vectors platform. Detailed information on the Sputnik V vaccine, the technological platform of human adenoviral vectors, and other details are available at sputnikvaccine.com
On September 4, a research paper on the results of Phase I and Phase II clinical trials of the Sputnik V vaccine was published in one of the leading international medical journals The Lancet. Phase I and Phase II trials demonstrated no serious adverse events and a stable immune response in 100% of participants.
Post-registration clinical trials of Sputnik V vaccine involving 40,000 volunteers are currently ongoing. First results of these trials are expected to be published in October-November 2020.
Health safety of the human adenovirus vaccines has been proven by more than 75 international publications and 250 clinical trials showing greater safety track record of human adenoviral vectors versus novel unproven technologies such as monkey adenoviral vectors or mRNA.
Kirill Dmitriev, CEO of the Russian Direct Investment Fund, said:
“Our Mexican partners clearly understand the advantage of the Russian vaccine Sputnik V compared to other vaccine candidates. In particular, they highlight a much greater safety track record of human adenoviral vectors versus novel technologies such as monkey adenoviral vectors or mRNA. Safety of human adenoviral vectors used in Sputnik V has been proven over decades in over 250 clinical studies as human adenovirus has been shown to be the safest and the most “organic for humans” vaccine delivery mechanism as human adenovirus coexists with humans for over 100,000 years. Unlike for well studied human adenoviral vector there were no long term studies for novel vaccines based on mRNA and monkey adenovirus. That is why a recent survey revealed that 66% of Mexicans express confidence in the Russian vaccine. We have agreed to deliver the large batch of Sputnik V vaccine to Mexico which will help 25% of the Mexican population to receive access to the safe and effective vaccine”.
Kirill Dmitriev has earlier published an Op-ed on advantages of human adenoviral vectors platform in comparison with other vaccine production technologies at: https://sputniknews.com/columnists/202009071080382164-questions-on-russias-sputnik-v-vaccine-answered/
Survey on confidence of Mexicans in the Russian-produced vaccine is available at: https://www.elfinanciero.com.mx/nacional/vacuna-rusa-contra-covid-19-la-que-mas-confianza-le-da-a-los-mexicanos/
Russian Direct Investment Fund (RDIF) is Russia's sovereign wealth fund established in 2011 to make equity co-investments, primarily in Russia, alongside reputable international financial and strategic investors. RDIF acts as a catalyst for direct investment in the Russian economy. RDIF’s management company is based in Moscow. Currently, RDIF has experience of the successful joint implementation of more than 80 projects with foreign partners totaling more than RUB1.9 tn and covering 95% of the regions of the Russian Federation. RDIF portfolio companies employ more than 800,000 people and generate revenues which equate to more than 6% of Russia’s GDP. RDIF has established joint strategic partnerships with leading international co-investors from more than 18 countries that total more than $40 bn. Further information can be found at rdif.ru
Landsteiner Scientific, established in 1998, is a vertically integrated, privately held pharmaceutical company headquartered in Mexico City. The company’s portfolio consists of more than 100 products and over 300 SKU’s that cover the demand for the export market, private and the main public health institutions in Mexico. Further information can be found at www.landsteiner.com/en/laboratory/
For additional information contact:
Russian Direct Investment Fund
Tel: +7 495 644 34 14, ext. 2395
Mobile: +7 916 110 31 41
Andrew Leach / Maria Shiryaevskaya
Tel: +44 (0) 20 7796 4133